‘Global Bio-Mems & Microfluidics Market Worth Over $2.8 Billion In 2017’ Says Visiongain Report

14 August 2017
Pharma

Visiongain’s new report World Bio-MEMS & Microfluidics Market Forecasts 2017-2027: Revenue Prospects by Type (Implantable, Biosensors, Stents, Drug Delivery, Biochips, Accelerometers, Injectable, Microneedles, Micromodules, Inhalers, Catheters, Micro Motors), Application (Diagnostic, Therapeutic, Tissue Engineering), End-User (Pharmaceutical Industry, Hospitals, Research Centres) and Geography indicates that the global Bio-MEMS & Microfluidics market will see over $2.8bn in revenue in 2017.
The lead analyst of the report said:

“Micro-electro mechanical systems (MEMS) refers to the technology of microscopic devices, in particular, those with mechanical parts. Bio-MEMS therefor refer to the microscopic devices and microfabrication technologies which are suitable for biological applications. Microfluidics instead deals with the operation, performance and exact control of fluids which are constrained to a small (sub-millimeter) scale. These systems are broadly used for biological and biomedical purposes. In addition, bio-MEMS are also used for clinical diagnostics and research and development in the healthcare sector for numerous applications. For instance, the introduction of accelerometers in pacemakers have revolutionized the treatment of cardiac diseases. Further, using bio-MEMS devices there is a possibility of improving the delivery of transdermal drugs, which are currently limited to passive diffusion devices.

Rising demand to treat critically ill patients and use of artificial limbs and the treatment nerve problems have been a major factor for the growth of bio MEMS market. Uptake of microfluidics in a wide range of biomedical applications for diagnostic and analytical purposes as well as enhanced detection of pathogens and viruses using bio-MEMS are other major factors influencing the growth of this market. In addition, complex manufacturing procedures for MEMS and sophisticated fabrication techniques has been a core restraint for the growth of this market. Furthermore, the expensive nature of this technology and its reliance on a technologically advanced medical infrastructure has made adoption of bio-MEMS comparatively more difficult. Hence, some governments are introducing new reimbursement programs and increasing healthcare infrastructure to allow for these new technologies to become more widely adopted. This is creating more lucrative opportunities for top players to invest in emerging economies such as China and India.

The global bio-MEMS and microfluids market is segmented based on type, application and end user. Based on type the market is classified into implantable bio-MEMS, injectable bio-MEMS, and other devices. Further, based on application the market is classified into diagnostics, therapeutics, tissue engineering and others. Furthermore, based on end user it is segmented for the pharmaceutical industry, hospitals, research centres and others. ”

The 206-page report contains 204 tables, charts and graphs that add visual analysis in order to explain developing trends within the Bio-MEMS & Microfluidics market. Visiongain provides revenue forecasts for the period 2017-2027 for the leading Bio-MEMS & Microfluidics software submarkets, segmented by type, including forecasts for Implantable, Biosensors, Stents, Drug Delivery, Biochips, Accelerometers, Injectable, Microneedles, Micromodules, Inhalers, Catheters and Micro Motors. The market is also segmented by application, with forecasts for Diagnostic, Therapeutic and Tissue Engineering from 2017-2027. In addition, the Bio-MEMS & Microfluidics market is segmented by end-user, with forecasts for Pharmaceutical Industry, Hospitals, Research Centres.

The 206-page report offers market forecasts and analysis for 7 key regional and 17 key national markets. In addition, the report contains a dedicated leading companies’ chapter covering 10 companies leading the Bio-MEMS & Microfluidics field in detail.

The World Bio-MEMS & Microfluidics Market Forecasts 2017-2027: Revenue Prospects by Type (Implantable, Biosensors, Stents, Drug Delivery, Biochips, Accelerometers, Injectable, Microneedles, Micromodules, Inhalers, Catheters, Micro Motors), Application (Diagnostic, Therapeutic, Tissue Engineering), End-User (Pharmaceutical Industry, Hospitals, Research Centres) and Geography report will be of value to anyone who wants to better understand the Bio-MEMS & Microfluidics market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Bio-MEMS & Microfluidics industry.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business conferences, newsletters, management reports and e-zines focusing on the automotive, chemical, cyber, defence, energy, pharmaceutical, materials and telecoms sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever